EDAP TMS S.A.
EDAP TMS S.A. develops and markets minimally invasive medical devices for urological diseases. The company operates through HIFU, ESWL, and Distribution Services segments. HIFU segment offers devices for treating prostate cancer and other clinical indications. ESWL division manufactures lithotripters for treating urinary tract stones. Distribution division markets and distributes medical products from third parties. The company sells products directly or through distributors and agents. EDAP TMS S.A. serves hospitals, clinics, and research institutions.
Overview
Sector
Medical Distribution
Strengths
- Price to book ratio (1.11) is lower than the sector mean (35.33).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (57.72).
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (33.87%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (40.52).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.1 |